PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

Slides:



Advertisements
Similar presentations
Copyright © 2006 American Medical Association. All rights reserved.
Advertisements

Change (with 95% CI) in outcomes by duration of type 2 diabetes
Framework for understanding obesity in children and youth.
Rate of provision of PCC
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.
PWD confidence with key diabetes management activities.
Postprandial glucose flux in nondiabetic controls.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
Relationship between self-reported adherence to USPSTF/ADA guidelines and evidence from EMR.† The concordance analysis was performed on only 281 surveyed.
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Reena Oza-Frank, MS-MPH, RD: Emory University (EU)
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.
Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.
Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.
Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.
Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.
Weight loss and A1C reduction over time in the Look AHEAD and IDOLc studies. Weight loss and A1C reduction over time in the Look AHEAD and IDOLc studies.
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.
Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.
(A–B) Differences in fat oxidation during the hyperinsulinemic euglycemic clamp between African–American and non-Hispanic white women after 7 days of a.
X-bar and S control charts of LOS
Median percentage weight change (left panels) and median weight (right panels) by birth weight groups as a function of time after (A) vaginal delivery.
Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.
When queried about the supply of endocrinologists to manage diabetes, respondents felt that there are not enough endocrinologists. When queried about the.
Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.
Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),
 Statistical process control chart for adverse drug events (ADEs) per 1000 doses of medication dispensed during the entire period of audit from January.
Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.
Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause.
Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.
HRs for prostate cancer by medication status.
Schematic representation of the natural history of obesity.
Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.
Fig. 3. Mean force and velocity during jumping
Stages of change for physical activity and dietary habits and associations with self-management scores (A) and HRQL scores (B). heiQ, Health Education.
Observed versus expected associations between the FGGRS and IMT
Incidence of childhood type 1 diabetes in Western Australia from 1985 through Incidence of childhood type 1 diabetes in Western Australia from 1985.
Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.
Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.
Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.
Proportion of responses to each of the six questions for the national Picker survey (black dots) and our study of 385 participants, who were all parents.
Adjusted ORs for pregravid, antepartum, and postpartum factors as predictors of likelihood that a woman will gain weight between 3 and 12 months postpartum.
ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,
Comparison of the ESMO-MCBS dual rule and the dual rule with PE thresholds exhibiting similar behaviour: %acceptance of maximal RB (solid line: RB rule)
A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.
Estimated daily P intake (in mg/d) from daily protein intake (in g/d) in 107 MHD patients from the NIED Study (30). Estimated daily P intake (in mg/d)
Concordance between self-reported likelihood to screen eligible patients as per ADA/USPSFT criteria and evidence from EMR. ADA, American Diabetes Association;
Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.
Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Jay S. Kaufman, PhD, Sam Harper, PhD  The American Journal of Medicine 
Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.
Survival Distributions for Positions Used in Practice and Development of MSDs Legend: Horizontal lines represent time intervals. Survival Distributions.
Pathway to initial antihypertensive therapy in patients with diabetes
The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.
Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)
Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)
Absolute survival probability (per cent who have not quit successfully) of reported quit attempts of longer than 1 year during the first 18 months of observation.
Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.
Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.
The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.
Change in first-phase insulin response (A) and pancreas triglyceride content (B) in responders and nonresponders at baseline (hatched bars), after VLCD.
Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,
Benchmarking scatterplot for non-ICU units.
Presentation transcript:

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their diabetes. Most reported engaging in self-management activities in the 6 months prior to the survey. Vertical lines = activities to prevent weight gain and lose weight, and dietary planning; dots = engagement in physical activity; and solid black = use of medication. Linda J. Piccinino et al. Diabetes Spectr 2017;30:95-100 ©2017 by American Diabetes Association